Becton, Dickinson and Company

NYSE:BDX Voorraadrapport

Marktkapitalisatie: US$68.9b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Becton Dickinson Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Becton Dickinson is de winst gegroeid met een gemiddeld jaarlijks percentage van 12%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 11.5%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 3.1% per jaar. Het rendement op eigen vermogen van Becton Dickinson is 5.6%, en het heeft een nettomarge van 7.4%.

Belangrijke informatie

12.0%

Groei van de winst

11.0%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie8.9%
Inkomstengroei3.1%
Rendement op eigen vermogen5.6%
Nettomarge7.4%
Volgende winstupdate07 Nov 2024

Recente prestatie-updates uit het verleden

Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings

Feb 08
Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings

Recent updates

Here's Why Becton Dickinson (NYSE:BDX) Can Manage Its Debt Responsibly

Sep 30
Here's Why Becton Dickinson (NYSE:BDX) Can Manage Its Debt Responsibly

Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery

Sep 13

Becton, Dickinson And Company: Somewhat Undervalued, A Very Moderate Buy

Aug 06

Why We're Not Concerned About Becton, Dickinson and Company's (NYSE:BDX) Share Price

Jul 16
Why We're Not Concerned About Becton, Dickinson and Company's (NYSE:BDX) Share Price

An Intrinsic Calculation For Becton, Dickinson and Company (NYSE:BDX) Suggests It's 36% Undervalued

Jun 27
An Intrinsic Calculation For Becton, Dickinson and Company (NYSE:BDX) Suggests It's 36% Undervalued

Is Becton Dickinson (NYSE:BDX) Using Too Much Debt?

May 24
Is Becton Dickinson (NYSE:BDX) Using Too Much Debt?

Becton, Dickinson and Company: Stagnating All Along

May 16

Investors Still Waiting For A Pull Back In Becton, Dickinson and Company (NYSE:BDX)

Mar 23
Investors Still Waiting For A Pull Back In Becton, Dickinson and Company (NYSE:BDX)

Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX)

Feb 29
Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX)

Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings

Feb 08
Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings

Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Feb 03
Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Feb 01
These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play

Jan 22

Becton Dickinson's (NYSE:BDX) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 30
Becton Dickinson's (NYSE:BDX) Shareholders Will Receive A Bigger Dividend Than Last Year

Becton, Dickinson And Company: Strong Q4 But Clouded By 75bps Growth Headwind From China In FY24

Nov 13

Becton Dickinson's (NYSE:BDX) Upcoming Dividend Will Be Larger Than Last Year's

Nov 12
Becton Dickinson's (NYSE:BDX) Upcoming Dividend Will Be Larger Than Last Year's

Becton, Dickinson and Company's (NYSE:BDX) Intrinsic Value Is Potentially 26% Above Its Share Price

Nov 06
Becton, Dickinson and Company's (NYSE:BDX) Intrinsic Value Is Potentially 26% Above Its Share Price

With EPS Growth And More, Becton Dickinson (NYSE:BDX) Makes An Interesting Case

Oct 05
With EPS Growth And More, Becton Dickinson (NYSE:BDX) Makes An Interesting Case

Becton, Dickinson Stock Is A Hold, Here's Why

Oct 04

Becton, Dickinson: Ahead Of Schedule, Undervalued, And With Some Positive Drivers

Aug 30

We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt

Aug 13
We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt

Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Jul 28
Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Here's Why We Think Becton Dickinson (NYSE:BDX) Is Well Worth Watching

Jun 22
Here's Why We Think Becton Dickinson (NYSE:BDX) Is Well Worth Watching

Becton, Dickinson and Company: Still Not Very Healthy

Jun 20

Becton, Dickinson: Business Should Beat H2 2023 Expectations

Jun 08

These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Apr 22
These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Is Now The Time To Put Becton Dickinson (NYSE:BDX) On Your Watchlist?

Mar 20
Is Now The Time To Put Becton Dickinson (NYSE:BDX) On Your Watchlist?

Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Mar 05
Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Becton, Dickinson HPV test Onclarity gets FDA nod for expanded use

Feb 21

Becton, Dickinson wins FDA nod for flu, COVID, RSV combo test

Feb 08

Becton, Dickinson Q1 2023 Earnings Preview

Feb 01

Becton, Dickinson declares $0.91 dividend

Jan 24

Opbrengsten en kosten

Hoe Becton Dickinson geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NYSE:BDX Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2419,8281,4594,8471,169
31 Mar 2419,7161,3644,8291,175
31 Dec 2319,4921,2654,8431,214
30 Sep 2319,3721,4704,8171,237
30 Jun 2319,0461,5824,8481,256
31 Mar 2318,8091,5564,7911,266
31 Dec 2218,7381,4864,7511,255
30 Sep 2218,8701,5454,7261,256
30 Jun 2218,9581,4124,7741,324
31 Mar 2218,9241,4304,8451,339
31 Dec 2118,5341,0794,7501,302
30 Sep 2119,1311,5144,7201,279
30 Jun 2119,0661,4864,6321,210
31 Mar 2118,3131,3794,4091,142
31 Dec 2018,2071,5074,3461,117
30 Sep 2016,0742454,1781,039
30 Jun 2016,9177864,2161,067
31 Mar 2017,4149234,3131,057
31 Dec 1917,3557604,3791,044
30 Sep 1917,2901,0814,3341,032
30 Jun 1917,1087844,3451,039
31 Mar 1917,0369264,3531,063
31 Dec 1817,0638944,3251,071
30 Sep 1815,9831594,0291,004
30 Jun 1814,7476213,689947
31 Mar 1813,503-993,325857
31 Dec 1712,2512942,991783
30 Sep 1712,0931,0302,953770
30 Jun 1712,1587592,947807
31 Mar 1712,3211,3142,957827
31 Dec 1612,4191,3092,966823
30 Sep 1612,4839763,005828
30 Jun 1612,3121,1392,966771
31 Mar 1612,2348102,988743
31 Dec 1511,2176882,767690
30 Sep 1510,2826952,563632
30 Jun 159,4108152,350570
31 Mar 158,4481,0792,127529
31 Dec 148,4681,1502,141527
30 Sep 148,4461,1852,145524
30 Jun 148,3459742,117522
31 Mar 148,2399412,102506
31 Dec 138,1699302,091502

Kwaliteitswinsten: BDX heeft een grote eenmalige verlies van $752.0M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th June, 2024.

Groeiende winstmarge: De huidige netto winstmarges (7.4%) BDX } zijn lager dan vorig jaar (8.3%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: De winst van BDX is de afgelopen 5 jaar met 12% per jaar gegroeid.

Versnelling van de groei: De winstgroei BDX is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: BDX had het afgelopen jaar een negatieve winstgroei ( -7.8% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Medical Equipment ( 7.9% ).


Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 5.6% ) van BDX wordt als laag beschouwd.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden